Edition:
United Kingdom

Alnylam Pharmaceuticals Inc (ALNY.OQ)

ALNY.OQ on NASDAQ Stock Exchange Global Select Market

75.66USD
13 Dec 2018
Change (% chg)

$-3.84 (-4.83%)
Prev Close
$79.50
Open
$79.70
Day's High
$80.70
Day's Low
$74.88
Volume
348,300
Avg. Vol
328,768
52-wk High
$153.80
52-wk Low
$63.71

Select another date:

Thu, Sep 27 2018

Early approval of Alnylam's gene-silencing drug in question

Alnylam Pharmaceuticals Inc said on Thursday it might have to hold off on plans to seek an accelerated approval for its gene-silencing drug, which showed effectiveness in a late-stage trial based on early data.

UPDATE 4-Early approval of Alnylam's gene-silencing drug in question

* Co still plans to discuss potential early approval with FDA

UPDATE 1-Alnylam's gene silencing drug wins FDA approval

Aug 10 Alnylam Pharmaceuticals Inc's drug for a rare hereditary disease won U.S. regulatory approval on Friday, becoming the first approved treatment from a new class of medicines that use gene silencing technology.

Alnylam's gene silencing drug wins FDA approval

Alnylam Pharmaceuticals Inc's drug for a rare hereditary disease won U.S. regulatory approval on Friday, becoming the first approved treatment from a new class of medicines that use gene silencing technology.

Alnylam's gene silencing drug wins FDA approval

Aug 10 Alnylam Pharmaceuticals Inc's drug for a rare hereditary disease won U.S. regulatory approval on Friday, becoming the first approved treatment from a new class of medicines that use gene silencing technology.

Select another date: